Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

Halozyme. "We look forward to the study investigators presenting the updated study results at the poster session and ensuing discussion."

Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Approximately 124 patients will participate in the study and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. Secondary endpoints of the trial include clinical evaluation of patient response in both treatment arms by tumor biopsy hyaluronan (HA) status.

Halozyme is also developing a HA diagnostic tool that will help evaluate potential treatment benefit based on HA levels for use in the randomized Phase 2 trial. Clinically validating this HA-diagnostic approach in the pancreatic cancer trial may also provide proof-of-concept for use of PEGPH20 in other HA-rich tumor types.

Halozyme Abstracts at ASCO:

  • Poster Presentation/Discussion: (E Hall D1): "A Phase 1b Study of Gemcitabine Plus PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in Patients with Stage IV Previously Untreated Pancreatic Cancer" will be presented by Sunil R. Hingorani M.D ., Ph.D., Fred Hutchinson Cancer Research Center on Monday, June 3 at 1:15PM-5:15PM CDT; discussion from 4:45 PM-5:45PM CDT. (Abstract #4010)
  • Educational Book Abstract: "Pharmacokinetic (PK)/Pharmacodynamic (PD) Results From a Phase 1b Study of PEGylated Hyaluronidase PH20 (PEGPH20) in Combination with Gemcitabine (Gem) in Patients with Pancreatic Cancer" (Abstract # e15005)

*33 percent response rate reported in the ASCO abstract based on partial data available at the time of abstract submission.

About Pancreatic Cancer
In most patients diagnosed with metastat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader ... the quarter ending June 30, 2015. Highlights included: , ... , The final cost of the Sarnia plant ... above the high end of the estimate communicated at ... , The company announced commercial collaborations in two ...
(Date:8/4/2015)... Calif. , Aug. 4, 2015 Trigemina, ... development of non-narcotic, nasally delivered, analgesic drug products, announced ... M.D., to the position of chief medical officer. Dr. ... to Trigemina, much of which has been focused in ... thrilled to add Dr. Kori to our clinical team ...
(Date:8/4/2015)... Mass. , Aug. 4, 2015  Blueprint Medicines ... developing highly selective kinase drugs for genomically defined diseases, ... officer, will present a company overview at the 2015 ... at 1:20 p.m. EDT. A live webcast ... Investors section of the Blueprint Medicines website at ...
(Date:8/4/2015)... , Aug. 4, 2015   California Cryobank Stem ... acquisition of LifeLine Cryogenics, an east coast cord blood ... New York tristate area. LifeLine clients will ... prepaid contracts will be honored. Since 1991, ... offering storage of sperm, eggs, embryos, and cord blood ...
Breaking Biology Technology:BioAmber Reports Second Quarter 2015 Financial Results 2BioAmber Reports Second Quarter 2015 Financial Results 3BioAmber Reports Second Quarter 2015 Financial Results 4BioAmber Reports Second Quarter 2015 Financial Results 5BioAmber Reports Second Quarter 2015 Financial Results 6BioAmber Reports Second Quarter 2015 Financial Results 7BioAmber Reports Second Quarter 2015 Financial Results 8BioAmber Reports Second Quarter 2015 Financial Results 9BioAmber Reports Second Quarter 2015 Financial Results 10BioAmber Reports Second Quarter 2015 Financial Results 11BioAmber Reports Second Quarter 2015 Financial Results 12Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3FamilyCord Announces Acquisition of LifeLine Cryogenics 2
... , SEATTLE, July 30 Dendreon Corporation (Nasdaq: DNDN ... a.m. PT; 11:30 a.m. ET to review second quarter 2009 financial results. Access ... Time: 11:30 AM ET /8:30 ... Dial-in: 1-877-548-7903 (domestic) or +1-719-325-4873 (international), ...
... LAUSANNE, Switzerland and MEDFORD, Massachussets, ... biopharmaceutical group,of companies with a focus on the ... and MSM Protein Technologies (MSM), a human,antibody drug ... membrane proteins, announce the signature of an exclusive,agreement ...
... , , PLEASANTON, Calif., ... (Nasdaq: THOR ), a world leader in device-based ... hearts, and HeartWare International, Inc. (Nasdaq: HTWR ; ... announced today that the United States Federal Trade Commission ("FTC") ...
Cached Biology Technology:Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 3Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 4U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 2U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 3U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 4
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... cap has been a focal point of recent climate change ... warming than the larger Antarctic ice sheet. Yet while the ... not clear how much this is contributing to rising sea ... such research was defined at a recent workshop organised by ...
... professor Karen Warkentin, working at the Smithsonian Tropical ... frog embryos at a very early developmental stage ... reported in the Nov. 7, 2008 issue of ... initial responses to the environment may be critical ...
... spread of West Nile virus in North America over the ... the continent, according to an article in the November issue ... little known before its emergence in New York in 1999, ... , West Nile virus has killed hundreds of millions of ...
Cached Biology News:What is really happening to the Greenland icecap? 2Red-eyed treefrog embryos actively avoid asphyxiation inside their eggs 2
...
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
ABI Plant AFLP Kits • EcoRI-ACA AFLP Amplification Primers...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Biology Products: